Tobin Schilke, CFO at Revance Therapeutics, Inc. (RVNC), sold 1,701 shares at $25.04 ($43K) on 2023-07-03, disclosed to the SEC on 2023-07-05.
Scheduled sale ($43k) by CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RVNC | SELL | 2023-06-05 | $181K | — | Filing → |
| RVNC | SELL | 2023-05-16 | $1.5M | — | Filing → |
| RVNC | SELL | 2023-05-02 | $203K | — | Filing → |